While the combined use of bevacizumab with chemotherapy did not improve OS or PFS in patients with RM-NPC, it demonstrated a notable improvement in ORR, second only to the combination of PD-1 inhibitors and chemotherapy. Here, PDCD1 is linked to nasopharyngeal carcinoma.